Semafore Pharmaceuticals, Inc.

Gilead Sciences Inc. 's acquisition of Calistoga Pharmaceuticals Inc. for $375 million up front February 22 is the richest deal yet for an emerging class of cancer drugs that many companies large

Early bets placed on PI3K pan-selective inhibitors may pay off, but smart money lately has been focused on isoform-selective inhibition of this signaling pathway implicated in cancer, inflammation, an

Inhibiting PI3K enzyme isoforms 10931 North Torrey Pines Road Suite 103 La Jolla, CA 92037 Phone: (858) 768-6500 Web Site: www.intellikine.com Contact: Troy Wilson, PhD, CEO Industry Segment: Biotechn

"Best of the Blog" is a monthly column highlighting the best of our free online content at www.windhover.com/blog . In May and June, Windhover’s editorial staff posted nearly 100 articles to the si